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ABSTRACT
Raltegravir (MK-0518) is the first integrase (IN) inhib-
itor to be approved by the US FDA and is currently
used in clinical treatment of viruses resistant to
other antiretroviral compounds. Virological failure
of Raltegravir treatment is associated with muta-
tions in the IN gene following two main distinct
genetic pathways involving either the N155 or Q148
residue. Importantly, in most cases, an additional
mutation at the position G140 is associated with
the Q148 pathway. Here, we investigated the viral
DNA kinetics for mutants identified in Raltegravir-
resistant patients. We found that (i) integration is
impaired for Q148H when compared with the wild-
type, G140S and G140S/Q148H mutants; and (ii) the
N155H and G140S mutations confer lower levels of
resistance than the Q148H mutation. We also char-
acterized the corresponding recombinant INs prop-
erties. Enzymatic performances closely parallel
ex vivo studies. The Q148H mutation ‘freezes’ IN
into a catalytically inactive state. By contrast, the
conformational transition converting the inactive
form into an active form is rescued by the G140S/
Q148H double mutation. In conclusion, the Q148H
mutation is responsible for resistance to Raltegravir
whereas the G140S mutation increases viral fitness
in the G140S/Q148H context. Altogether, these
results account for the predominance of G140S/
Q148H mutants in clinical trials using Raltegravir.
INTRODUCTION
Integrase (IN) inhibitors constitute a new class of anti-
retroviral agents blocking HIV-1 IN activity (1).
HIV-1 IN is one of the three enzymes essential for viral
replication. IN is responsible for integration of the
reverse-transcribed double-stranded blunt-ended DNA
into the host cell DNA and, is therefore an attractive
target for anti-HIV drugs. IN catalyses two reactions:
30-end processing and strand transfer (2). During 30-end
processing, the terminal GpT dinucleotides are cleaved
from the 30-end of each long terminal repeat (LTR), pro-
ducing CpA 30-hydroxyl ends. This reaction takes place
within a nucleoprotein complex known as the preintegra-
tion complex (PIC). The PIC is then transported through
the nuclear pore into the nucleus, where strand transfer
occurs. During this second step, IN transfers both newly
exposed 30-extremities of the viral DNA into the target
DNA by a one-step transesteriﬁcation reaction, resulting
in full-site integration (3).
To date, only integrase strand transfer inhibitor
(INSTI) have been shown to have a potent antiviral activ-
ity in vivo (4,5). Raltegravir (RAL), a drug of the INSTI
group, was recently approved for therapeutic use after
clinical assays demonstrated a rapid, potent and sustained
antiretroviral eﬀect in patients with advanced HIV-1 infec-
tion (6). Because of its mechanism of action, this novel
antiviral agent (ARV) is likely to be active against viruses
resistant to other class of antiretroviral drugs such as
nucleoside reverse transcriptase inhibitors (NRTI), non-
nucleoside reverse transcriptase inhibitors (NNRTI),
Protease (PI) and entry inhibitors. Indeed, RAL has
already proven to be active when used with an optimized
regimen in patients infected with drug-resistant viruses (6).
However, resistance mutations are present in the IN gene
of patients who fail to respond to RAL treatment.
Resistance data from a clinical study at the Hospital
Pitie ´ -Salpe ˆ trie ` re show that resistance to RAL develops
in two main pathways, either through mutations of the
N155 or the Q148 residue (7). This study also highlights
two important observations: (i) the N155 pathway may
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Q148H mutation occurs simultaneously with the G140S
mutation. The Q148H mutation may be present as a sin-
gle mutation at the beginning of the treatment, but the
G140S mutation appears after a few weeks of treatment.
Thus, the Q148 and G140 residues clearly play a key role
in the treatment failure on RAL. Other large-scale studies
have shown that the Q148 pathway is the most frequently
observed of the two pathways in RAL treatment failure
(8). Others mutations, such as the E92 and E157Q, have
also been described (7).
We investigated the impact of the two main genetic
resistance pathways (N155H and G140S/Q148H), on
viral replication and the catalytic properties of recombi-
nant INs. In particular, we investigated the eﬀect of the
G140S/Q148H double mutation, by constructing both the
Q148H and G140S single mutants as well as the double
mutant. We also studied the eﬀect of IN background
(laboratory strain or patient) on the properties of the
enzymes. We found that the Q148H mutation caused resis-
tance to RAL when present alone. However, this mutation
severely impaired viral replication kinetics in addition to
the catalytic activity of the recombinant IN. The G140S
mutation did not confer strong resistance, but restored the
replication capability of the Q148H mutant. Accordingly,
the in vitro activity of the G140S/Q148H mutant can reach
a wild-type level of activity while the single mutant Q148H
cannot. Our kinetic study reveals that Q148H is a catalytic
mutant blocked in an inactive conformation. The G140S
mutation induces a conformational transition compatible
with activity. Thus, the combination of these two muta-
tions results in a virus that is both capable of replication
and highly resistant to RAL. Finally, we found that the
G140S/Q148H mutant was much more resistant than
the N155H mutant. These ﬁndings are consistent with
the switch from the N155 to the Q148 pathway observed
after a few weeks of RAL treatment.
MATERIALS AND METHODS
Cells and viruses
MT4 cells were cultured in RPMI 1640 containing 10%
fetal calf serum. 293T and HeLa-P4 cells were cultured
in Dubelcco’s modiﬁed Eagle medium supplemented
with 10% fetal calf serum, 100 units penicillin/ml
(Invitrogen), and 100mg streptomycin/ml (Invitrogen).
HIV-1 IN mutants were generated as previously
described. Brieﬂy, the fragment encoding IN of the repli-
cation-competent pNL43 virus was digested with AgeI
and EcoRI, inserted into the Bluescript vector and IN
mutants were obtained by mutagenesis (Quick change
mutagenesis kit, Stratagene). We studied the E92Q,
G140S, Q148H, N155H and G140S/Q148H mutations in
a pNL43 background. The constructs were checked by
sequencing and the fragment was then inserted into
pNL43. HIV-1 virus stocks of all mutants were prepared
by transfecting 293T cells. Transfection assays were
carried out by the calcium phosphate method. Viral
supernatants, 48h post-transfection, were ﬁltered
through a 0.45mm-pore-size-ﬁlter and frozen at  808C.
HIV-1 p24
gag antigen contents in viral supernatants were
determined by enzyme-linked immunosorbent assay
(Perkin-Elmer Life Sciences).
HIV infectivity assay
Single-cycle titers of the virus were determined in HeLa-P4
cells. HeLa-P4 cells are HeLa CD4 LTR-LacZ cells in
which lacZ expression is induced by the HIV transactiva-
tor protein Tat, making it possible to quantify HIV-1
infectivity precisely from a single cycle of replication.
Cells were infected, in triplicate, in 96-well plates, with
virus (equivalent of 3ng of p24
gag antigen). The single-
cycle titers of viruses were determined 48h after infection
by quantifying b-galactosidase activity in P4 lysates in a
colorimetric assay (the CPRG assay) based on the cleav-
age of chlorophenol red-b-D-galactopyranoside (CPRG)
by b-galactosidase. For IC50 determination, cells were
infected with viruses and grown in the presence of
increasing concentrations of RAL or the diketo-acid
L731-988. The 50% inhibitory concentration (IC50) was
determined as the drug concentration giving 50%
inhibition of b-galactosidase levels with respect to
untreated infected cells. Cell survival was also estimated
with a standard MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
-diphenyltetrazolium bromide) assay.
Viral infections
MT4 cells were concentrated at 2 10
6/ml and infected
with viruses (50ng of p24
gag antigen per 10
6 cells). When
required, cells were treated with 500nM RAL inhibitor
(Merck & Co.) or 25mM zidovudine (AZT; Sigma)
before infection. In the experiment with RAL, the
medium containing the drug was replaced every three
days (to maintain drug concentration). At various time
points after infection, one to 3 million cells were harvested
and dry cell pellets were frozen at  808C until use.
DNA extraction andreal-time PCR
Total cell DNA was extracted with a QIAamp blood
DNA minikit (QIAGEN, Courtaboeuf, France).
Quantiﬁcations of total HIV-1 DNA, 2-LTR circles and
integrated HIV-1 DNA were performed by real-time PCR
on a LightCycler instrument (Roche Diagnostics) using
the ﬁt point method provided in the LightCycler quanti-
ﬁcation software, version 3.5 (Roche Diagnostics) as pre-
viously described (9).
Cell equivalents were calculated based on ampliﬁcation
of the b-globin gene (two copies per diploid cell) with
commercially available materials (Control Kit DNA;
Roche Diagnostics). 2-LTR circles, total and integrated
HIV-1 DNA levels were determined and expressed as
copy numbers per 10
6 cells.
Characterization of INprotein activity invitro
Two IN sequences, F4 and F12, obtained in a clinical
study and corresponding to the IN sequences of a patient
before and after treatment with RAL, respectively, were
expressed, as previously described (7). The F4 polymorph-
ism consists of eight mutations with respect to the
1194 Nucleic Acids Research, 2009, Vol. 37,No. 4‘laboratory’ WT pNL43 IN: K7Q, E11D, L101I, K127R,
I135V, I200L, V201I, I220L. F12 harbors these mutations
together with the G140S/Q148H double mutation in the
F4 background. The introduction of the entire sequence of
the IN gene with the G140S/Q148H mutation from the
patient into the pNL43 context did not result in a produc-
tive infection, suggesting that other viral proteins of the
patient were required for eﬃcient replication (data not
shown). The comprehension of the potential inﬂuences
of other viral proteins on viral replication is in progress
in our laboratory.
In parallel, the E92Q, G140S, Q148H, N155H and
G140S/Q148H mutations were obtained by site-directed
mutagenesis from pET-15b, containing the WT sequence.
The wild-type and mutant HIV-1 INs used for DNA-
binding and 30-processing assays were produced in
Escherichia coli BL21 (DE3) and puriﬁed under non-
denaturing conditions as previously described (10).
Steady-state fluorescence anisotropy-based assay
Steady-state ﬂuorescence anisotropy values (r) were
recorded on a Beacon 2000 Instrument (Panvera,
Madison, WI), in a cell maintained at 258Co r3 7 8C
under thermostatic control. The principle underlying the
anisotropy-based assay was published elsewhere for
DNA-binding (11,12) and 30-processing (13,14), respec-
tively. Brieﬂy, IN binding to ﬂuorescein-labeled DNA
(double-stranded 21-mer oligonucleotide (ODN) mimick-
ing the U5 viral DNA end) increases the r value, making it
possible to calculate the fractional saturation function:
([DNA
 IN]/[DNA]0). DNA-binding step was recorded at
258C, using ODNs ﬂuorescein-labeled at the 30-terminal
GT nucleotide. The percentage of complexes was then
calculated according to:
DNA
 INð%Þ¼
r   rfree
rsat   rfree
  100 1
where rfree and rsat are the anisotropy values characterizing
the free and bound oligonucleotides, respectively.
Following the DNA-binding step, the sample was then
shifted to a permissive temperature for the recording of
30-processing activity (378C). As the ﬂuorophore is linked
to the released dinucleotide, 30-processing activity signiﬁ-
cantly decreases the r value with respect to that for the
non-processed DNA. Activity can be calculated in ﬁxed-
time experiments, by disrupting all the IN/DNA
complexes with SDS (0.25% ﬁnal). The fraction of dinu-
cleotides released is given by:
Fdinu ¼
rNP   r
rNP   rdinu
2
where rNP and rdinu are the anisotropy values for pure
solutions of non-processed double-stranded ODN and
dinucleotide, respectively. The formation of IN/DNA
complexes and the subsequent 30-processing reaction
were performed by incubating ﬂuorescein-labeled
ODNs (4nM) with IN in 20mM Hepes pH 7.2, 1mM
dithiothreitol, 30mM NaCl and 10mM MgCl2.
Standard 30-processing and strand transfer activity tests
based on gel electrophoresis were performed as previously
described (10).
RESULTS
Resistance of viralmutants toRAL
Sequence analysis of clinical isolates obtained during RAL
treatment led to the identiﬁcation of various mutations at
speciﬁc positions. Two main proﬁles were identiﬁed, one
based on the N155H mutation and the other based on the
G140S/Q148H mutations, which seemed to be present
together in most cases. After RAL administration, only
mutations in the IN gene were observed (7).
We introduced IN mutations (i.e. N155H or E92Q or
G140S/Q148H) into a WT pNL43 background. Two other
constructs with single G140S or Q148H mutations were
analyzed in parallel. Levels of p24 production were deter-
mined 48h after transfection. They were found to be sim-
ilar for all mutations (Figure 1A). We can therefore
conclude that these mutations do not signiﬁcantly impair
virus assembly or the release step. HeLa-P4 cells were then
infected for 48h to study the early replication step. The
mutations clearly had diﬀerential eﬀects on viral infectiv-
ity (Figure 1B). The two single mutations, N155H and
E92Q, neither disrupt the early steps of replication
nor expression of integrated DNA, as shown by the
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Figure 1. p24 and infectivity of IN mutant viruses. (A) Quantiﬁcation
of p24 protein, 48h after transfection of 5mg of each virus DNA. (B)
Viral infectivity for WT and mutants. Viral infectivity was determined
in a single-cycle replication assay using HeLa p4 indicator cells and
3ng of p24 antigen for each virus. Cells were exposed to virus during
48h. Early steps of infections were assessed by measuring b-galactosi-
dase activity in cell extracts by the CPRG method. For panels A and B,
the results are expressed as percentages of the value obtained for the
WT. The data shown are the means of three independent experiments.
Nucleic Acids Research,2009, Vol.37, No. 4 1195corresponding b-galactosidase levels, which were similar
to the WT. However, the Q148H and G140S mutations
signiﬁcantly decreased viral infectivity (3-fold and 2-fold
less b-galactosidase expression for Q148H and G140S,
respectively, as compared with the WT level), probably
because of a defect in the integration process.
Interestingly, the combination of these two mutations in
the same virus resulted in levels of viral infectivity similar
to those of the WT and much higher than obtained with
the Q148H and G140S single mutations. These ﬁndings
suggest that these two point mutations individually
impair the viral infectivity but that their combination
results in a wild-type level of infectivity.
We investigated the mechanism underlying the eﬀects of
these mutations on resistance to RAL, by determining the
IC50 for each IN mutant (Figure 2A). The IC50 value
(10nM) obtained for the WT virus conﬁrmed the potency
of RAL as an inhibitor of HIV-1. At 24 or 72h, no cyto-
toxic eﬀects from the concentrations used in this experi-
ment were observed in the MTT assay after infection
(Figure 2B). G140S and E92Q mutants had slightly
higher IC50 values (30nM) than the WT. In sharp con-
trast, the N155H, Q148H and G140S/Q148H mutants had
much higher IC50 values, at 130, 450 and >1000nM,
respectively. Thus, all the mutants identiﬁed in clinical
trials using RAL were resistant to this compound, but to
diﬀerent extents. The same experiment was conducted
with the strand transfer inhibitor L,731-988, a diketo
acid which, similar to RAL, belongs to the INSTI
group. The resistance proﬁles observed with this drug fol-
lowed the same pattern as RAL (data not shown) but
the values obtained were in low micromolar range for
L,731-988, rather than in the nanomolar range as seen
with RAL. Thus DKA, a well-characterized drug and
RAL, both of which share the same mechanism of
action, probably bind to the same binding site, inhibiting
the strand transfer reaction by interfering with the binding
of target DNA to IN.
Effects ofmutations on viralDNA formsduring replication
We investigated the eﬀects of mutations during viral repli-
cation, by real-time PCR (qPCR) analysis, on the diﬀerent
viral nucleic acid species (total viral DNA, 2-LTR circles
and integrated viral DNA) in cells infected with WT virus
or resistant mutants.
Total viral DNA synthesis during the ﬁrst 24h after
infection was similar for all mutants studied, and the kinet-
ics of DNA synthesis were similar to those of the WT
(Figure 3A). Furthermore, for all mutant and WT viruses,
DNA synthesis peaked 10h after infection, as typically
reported in such studies (15), indicating that none of the
mutations signiﬁcantly aﬀected the timing of the reverse
transcription step. As a control, no viral DNA synthesis
was detected with the WT in the presence of 25mM AZT.
We performed the same experiment for the WT and the
G140S/Q148H mutant in the presence of 500nM RAL
(a concentration 50 times higher than the IC50 value
for the WT). Viral DNA synthesis levels were similar in
the presence and absence of RAL for both the WT and the
G140S/Q148H mutant (Figure 3A), conﬁrming the
absence of RAL eﬀect on the reverse transcription step.
We quantiﬁed total viral DNA synthesis at a later time
point to assess the ability of mutants to replicate in
infected cells. qPCR quantiﬁcation showed the kinetics
of total viral DNA accumulation to be similar for the
WT and all mutants, with the exception of the Q148H
virus, for which smaller amount of viral DNA were
detected, i.e. 5- and 10-fold less than for the WT virus,
39 and 64h after infection, respectively. The apparent dis-
crepancy between b-Gal assays and integration quantiﬁ-
cation of the G140S mutant will be further discuss in the
next section. For WT infection in the presence of RAL,
only a faint viral DNA signal was detected after the
reverse transcription step: viral DNA, was reduced by
10- and 100-fold, 39 and 64h after infection, respectively,
when compared with WT infection in the absence of RAL,
demonstrating the eﬃcacy of this compound for blocking
viral replication. In sharp contrast, RAL had only a
slight eﬀect on the DNA synthesis of the G140S/Q148H
mutant (DNA synthesis was reduced by 1.2-fold at
64h after infection), conﬁrming the strong resistance of
this double mutant. Moreover, Figure 3B clearly shows
the better ﬁtness of G140S/Q148H in comparison to the
single-mutant Q148H.
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Figure 2. Resistance of IN mutants to RAL. (A) HeLa p4 cells were
infected, in triplicate, with 3ng of each virus, in the presence of various
RAL concentrations. b-Galactosidase production was quantiﬁed by the
CPRG assay. Data from a representative experiment (performed three
times) is shown. The IC50 was determined as the concentration of RAL
inhibiting b-galactosidase production by 50% with respect to untreated
infected cells. (B) MTT assay. The MTT assay was performed 48 and
72h after infection for all viruses. For the WT and G140S/Q148H
mutant, the assay was performed with and without 500nM RAL.
The data shown are the means of three independent experiments.
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Nucleic Acids Research,2009, Vol.37, No. 4 1197Both eﬃcient IN inhibitors and mutations in the cata-
lytic triad DD35E of IN have been reported to cause a
decrease in the amount of integrated DNA, with a con-
comitant increase of 2-LTR circles (16,17), suggesting that
2-LTR circles molecules results from a defect in the inte-
gration process. We then analyzed the kinetics of 2-LTR
accumulation and quantiﬁed integrated viral DNA, to
obtain greater insight into the eﬀects of the mutations
and of RAL on the integration process (Figure 3C
and D). The percentages of 2-LTR circles and integrated
DNA viral forms are shown in Figure 3E. Again, our
results clearly demonstrate that the Q148H mutant was
more strongly aﬀected than other mutants, as shown by
the signiﬁcant decrease in the amount of integrated DNA
forms and the simultaneous accumulation of 2-LTR cir-
cles. A qualitatively similar but more pronounced eﬀect
was observed with the WT in the presence of RAL. No
integrated DNA was detected, despite the sensitivity of the
qPCR approach (9), demonstrating the eﬃciency of RAL
as an inhibitor of the integration process. Remarkably,
RAL had only a small eﬀect on the levels of 2-LTR circles
and integrated forms with the G140S/Q148H double
mutant (Figure 3E). Figure 3F shows the correlation
between accumulation of the episomic viral genome and
the decrease in the amount of integrated DNA. This cor-
relation supports the idea that the accumulation of 2-LTR
circles results principally from an integration defect.
We assayed the supernatant of infected cells for the
presence of viral particles, by quantifying p24 48 and
72h after infection, to determine whether viral production
was compatible with the amount of integrated DNA.
Consistent with the quantiﬁcation results obtained for
the diﬀerent DNA forms (Figure 3), only the production
of p24 by the WT in the presence of RAL and by the
Q148H mutant was severely impaired (p24 production
decreased by 25- and 6-fold, respectively) (Figure 4).
Figure 4 also conﬁrms the resistance of G140S/Q148H
as shown by the limited eﬀect of RAL on the p24 produc-
tion of the double mutant. The viral particles obtained
from all IN mutants were infectious (data not shown).
Thus, IN mutations have no crucial consequences for
the dynamics of viral replication, except the for the Q148H
mutant, which displayed high levels of 2-LTR circle accu-
mulation related to an integration defect. Therefore, the
similar proﬁle of this mutant as compared to mutants of
the catalytic triad strongly suggests a defect of IN at the
catalytic level (18). We then studied the eﬀect of the
Q148H and/or G140S mutations on 30-processing and
strand transfer activities using recombinant proteins.
G140S rescuesthe catalytic defectdue to the
Q148H mutation
The G140S/Q148H double mutation is one of the main
proﬁles identiﬁed in patients resistant to RAL. These
mutations seem to appear simultaneously or over a very
short period of time in patients treated with this com-
pound. We investigated the role of the G140 and Q148
residues in the resistance, by producing recombinant INs
harboring either the G140S or the Q148H mutation, and
the G140S/Q148H double mutant. In parallel, we also
obtained recombinant proteins encoding the entire IN
sequence, as found in patients with the double G140S/
Q148H mutation.
A plot of 30-processing activity (corresponding to 3h of
incubation at 378C) as a function of IN concentration
gave a characteristic bell-shaped curve, with activity peak-
ing at a concentration of about 200nM, for both WT IN,
expressed in NL-43 context (Figure 5A, left panel) or in
patients context before RAL treatment (Figure 5A, right
panel) in accordance with previous results (13,14). Under
the same conditions, the activities of the Q148H, G140S
and G140S/Q148H were severely impaired, with the
degree of impairment as follows: Q148H<<G140S/
Q148H G140S<WT (Figure 5). It is important to
note that both proteins, WT and G140S/Q148H, in the
patient background displayed stronger activity than INs
in the NL-43 context. We are currently investigating the
eﬀects of the polymorphism on intrinsic IN activity.
As the increase in the IN concentration did not com-
pensate for the defect in 30-processing activity of the
mutants (i.e. increasing the concentrations of mutant pro-
teins did not result in wild-type levels of activity, as shown
in Figure 5A), the defect was probably not because of a
decrease in the overall aﬃnity for the DNA substrate,
being instead due to a catalytic defect. Accordingly, quan-
tiﬁcation of IN–DNA complexes by steady state aniso-
tropy (Figure 5B), indicated that complex formation was
not altered by any type of mutation. Our activity data
after 3h of incubation highlight some discrepancies
between in vitro and ex vivo results, particularly for the
G140S/Q148H double mutant virus, which replicated as
well as the WT virus, despite the lower activity of the
corresponding recombinant IN.
To understand this apparent discrepancy, we next stud-
ied the entire 30-processing kinetics of WT and mutants.
Interestingly, the kinetics of processing for the G140S and
G140S/Q148H, although delayed in time as compared to
the WT (t1/2=20.8h for mutants, t1/2=4.1h for WT),
showed that these two mutants were able to reach WT
levels of activity (Figure 5C). Again, this result was
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Figure 4. p24 production. Viral particles released in the supernatant
were determined 48 and 72h after infection by quantiﬁcation of the
p24 protein (see Materials and methods section). The data shown are
the means of four independent experiments.
1198 Nucleic Acids Research, 2009, Vol. 37,No. 4independent of the context (NL-43 or patients) (compare
left and right panels). The sigmoidal nature of the kinetics
observed strongly suggests that IN must undergo a con-
formational transition to shift from a catalytically inactive
state to an active state (IN
I,IN
A). 30-Processing activity
as analyzed by gel-electrophoresis with standard proce-
dures (10) gave similar results (data not shown).
Moreover, quantiﬁcation of the product of the strand
transfer reaction indicated that, under conditions in
which the 30-processing levels of the G140S/Q148H
reached the WT levels, the yields of strand transfer are
similar for the WT and the double mutant. In fact, after
normalization by the 30-processing activity, we found that
the strand transfer eﬃciency was 6.5%, 2.2% and 5.5%
for WT, Q148H and G140S/Q148H mutants, respectively
(Figure 5C). In contrast to G140S and G140S/Q148H, the
single mutant Q148H appears to be more severely
impaired than the other mutants, with a 30-processing
activity increasing only slightly to 35%, after up to 50h
of incubation, with concomitant decrease in the yield of
strand transfer (Figure 5C). Most likely, the IN
I,IN
A
transition accounts for the slow single turn-over rate con-
stant characterizing IN (12). The eﬀect of the Q148H
mutation which strongly impairs this transition is reversed
by adding the G140S mutation. These two residues belong
to the catalytic loop 140–149, the ﬂexibility of which was
previously described to be essential for activity (19,20).
The Q148 residue was shown to be essential to establish
speciﬁc contacts with viral DNA (21,22). Our results,
showing that overall aﬃnity of the IN-DNA complex
was not inﬂuenced by the Q->H mutation at this position,
do not exclude a ﬁne repositioning of the catalytic loop
relative to the viral DNA end, leading to a non-competent
catalytic complex. Interestingly, two other mutations of
the catalytic loop (G149A and G149A/G140A) display
similar post DNA-binding defects (20). The residue
G140 participates in catalytic loop hinge formation and
its mutation could restore speciﬁc contacts compatible
with catalysis between the loop of the double mutant
and the viral DNA end. Simulation and molecular
dynamics (MD) studies on the catalytic loop of IN is
under progression in our laboratory. We have found
that the Q148 residue belongs to a V-shaped hairpin
(144–148) that can move in a gate-like manner toward
the active site as a rigid body. The G140 residue is not
directly involved in the ﬂexibility of the catalytic loop but
plays a critical role in controlling the overall motion of the
loop and ﬁnally in controlling its precise positioning rela-
tive to the phosphodiester bound to be cleaved (‘In Silico
study suggests that raltegravir-resistant mutations modify
the DNA recognition properties of HIV-1 Integrase’ by
Tchertanov et al., Third International Conference on
Retroviral Integrase; September 14–18, 2008).
DISCUSSION
To date, only INSTIs have been shown to be true inhibi-
tors of HIV-1 DNA integration. These compounds
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Figure 5. Comparative study of the DNA-binding and catalytic properties of wild-type and RAL-resistant INs. (A)3 0-Processing activity—after 3h
of incubation at 378C—as a function of IN concentration. 30-Processing activities were quantiﬁed as described in Materials and methods section,
using a 21-mer DNA substrate (4nM), with MgCl2 as a cofactor (10mM) in 20mM Hepes (pH 7.2), 1mM DTT and 30mM NaCl. (B) DNA binding
of wild-type and mutant INs. The DNA-binding step was assessed by steady-state ﬂuorescence anisotropy as described in Materials and methods
section. Experimental conditions were similar to those described in A. IN and DNA were incubated together for 15min before recording steady-state
anisotropy. (C) Kinetics of 30-processing for the diﬀerent proteins. IN concentration was 200nM. The same symbols were used in panels A, B and C:
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Nucleic Acids Research,2009, Vol.37, No. 4 1199speciﬁcally inhibit strand transfer and target the pre-
integration complex in vivo. RAL (or MK-0518) is a
member of the INSTI family. This IN inhibitor was the
ﬁrst to be approved by the FDA for the treatment of
AIDS. RAL is generally well tolerated although a recent
study suggested an association between RAL and rhabdo-
myolysis (23). It is currently undergoing late-stage clinical
trials with patients infected with multidrug-resistant HIV-
1 viruses. However, several mutations occur very rapidly,
within 11 weeks of beginning treatment. These mutations
are E92Q, N155H and the G140S/Q148H double muta-
tion, which seems to appear preferentially (8).
In this report, we analyzed the eﬀect of mutations intro-
duction in both the viral context and in the recombinant
IN, focusing our studies on the double mutant. Our data
demonstrate that each mutation described conferred resis-
tance, but the extent of that resistance diﬀered between
mutations. The G140S/Q148H double mutation confers
strong resistance to the drug and viral replication levels
similar to those of the WT virus. Importantly, the G140S
displays weak resistance (IC50=30nM) while the Q148H
is strongly resistant to RAL (IC50>700nM). Taken
together, these data suggest that resistance results princi-
pally from the Q148H mutation. In the viral context, all
mutants, including G140S, displayed replication kinetics
similar to those to the WT virus, with the exception of the
Q148H mutant which is characterized by a slower kinetic.
Consistently, all mutants are weakly impaired in the syn-
thesis of viral DNA as well as in their propensity to inte-
grate their genome and consequently to produce viral
particles with the notable exception of the Q148H
mutant. Its integration eﬃciency is 7-fold less in compar-
ison to the WT. These data demonstrate that, in the case
of the G140S/Q148H double mutant, the resistance to
RAL is due to the Q148H and that the G140S mutation
rescues the integration deﬁciency and thus the kinetic of
replication.
It is important to note that b-Gal assays using the
HeLa-P4 cells suggests that the G140S mutant was
impaired in the viral integration process, in accordance
with results of Nakahara et al. (24). However, we found
that the integration eﬃciency of the G140S was similar to
those found for the WT and G140S/Q148H double
mutant. To date, the reason of such discrepancy is not
clear but the type of cells used for integration quantiﬁca-
tion could be crucial in modulating the mutation impact,
especially in the case of the G140S mutation. Indeed,
Nakahara et al. (24) have found that the viral replication
was delayed in Jurkat cells but not in PBMC cells. Such a
diﬀerential response of the G140S mutation depending on
the cellular context could account for the lack of correla-
tion between b-Gal assays (Figure 1) and integration
quantiﬁcation (Figure 3).
These data were conﬁrmed by in vitro activity experi-
ments. We observed that G140S/Q148H IN, although
kinetically aﬀected as compared to the WT IN, displayed
WT levels of activity if the incubation time was increased
(kinetic mutant). The Q148H IN was much more severely
impaired and cannot reach the WT level of activity
(thermodynamic mutant). Our activity data—at long incu-
bation time—highlight a correlation between in vitro
activity of IN and viral replication. Nevertheless, the
slower kinetic of either G140S or G140S/Q148H, as seen
in vitro, had no eﬀect on the replication cycle of corre-
sponding viruses. It is possible that the slow conforma-
tional transition involving the ﬂexibility of the catalytic
loop (see Results section) may not be kinetically limiting
in the PIC context due to interactions with protein part-
ners. Taken together, we hypothesized that the Q148H
mutation primarily confers resistance to RAL. However,
this mutation severely impaired viral replication. The
G140S mutation counteracted this detrimental eﬀect for
the virus and increased viral ﬁtness. These data clearly
account for the high frequency of the G140S/Q148H
mutant in clinical trials. It is important to note that the
Q148H/R single mutation may occur 8 weeks after start-
ing RAL treatment. However, 8–10 weeks later, the
G140S mutation is also detected in patients. Our data of
the compensation of the Q148H replication eﬃciency by
the G140S explain why very rapidly after the administra-
tion of RAL, the G140S/Q148H mutant is detected. In
addition, our data demonstrate that the Q148H mutant
is more resistant to RAL in comparison to the N155H
mutant. This observation explains why the N155 pathway
often switched to the Q148 pathway. It is important to
note that, during the course of our study, similar results
were obtained by Nakahara et al. (24). The authors have
studied the Q148K/R and G140S mutations as well as the
G140S/Q148R and G140S/Q148K double mutants.
Mutants Q148K/R displayed reduced viral ﬁtness what-
ever the cell line studied (PBMC or Jurkat cells). In the
case of the G140S mutant, the viral ﬁtness is only delayed
in Jurkat cells. In accordance with our results, Nakahara
et al. have shown that the G140S mutation rescues the
ﬁtness of the Q148K/R mutant. Taken together, results
from Nakahara et al. and our study show that the
G140S mutation rescues the ability of the Q148H/K/R
mutants to replicate in cells while mutation of the Q148
residue is responsible for the resistance to the drug. Note
that the discrepancy concerning the nature of the muta-
tion (K, R in the Nakahara’s experiments and H in our
study) is only apparent since resistance mutation were not
obtained against the same anti-IN compound: S-1360 and
GSK-364735 were used by Nakahara et al. while, in this
study, we used RAL.
The development of strand transfer-speciﬁc inhibi-
tor classes is an important achievement for the IN
drug design. However, continued drug development is
required as the ability of HIV to replicate under therapeu-
tic pressure will undoubtedly lead to the emergence of
IN drug-resistant viral strains characterized by compara-
ble ﬁtness to WT such as the double mutant G140S/
Q148H.
To prevent from the appearance of cross-resistance,
other sites of IN must be targeted as already done for
the development of RT inhibitors. For example, sites
responsible for the oligomerization of IN or/and interac-
tions with cellular partners as LEDGF constitute good
candidates. The combination of several IN inhibitors in
optimal regimen will undoubtedly lead to optimal treat-
ment for patients.
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